Anti-JCV antibody index does not change during ocrelizumab-treatment

OBJECTIVE: To prospectively assess anti-JCV antibody index (AI) and its relationship to immunoglobulin levels in ocrelizumab-treated MS patients. METHODS: Monocentric prospective observational study over 24 months assessing anti-JCV AI and immunoglobulin levels in MS patients before and after initia...

Descripción completa

Detalles Bibliográficos
Autores principales: Rempe, Torge, Carlson, Aaron, Miravalle, Augusto, Gyang, Tirisham Victoria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522834/
https://www.ncbi.nlm.nih.gov/pubmed/33029356
http://dx.doi.org/10.1177/2055217320960510
_version_ 1783588267205066752
author Rempe, Torge
Carlson, Aaron
Miravalle, Augusto
Gyang, Tirisham Victoria
author_facet Rempe, Torge
Carlson, Aaron
Miravalle, Augusto
Gyang, Tirisham Victoria
author_sort Rempe, Torge
collection PubMed
description OBJECTIVE: To prospectively assess anti-JCV antibody index (AI) and its relationship to immunoglobulin levels in ocrelizumab-treated MS patients. METHODS: Monocentric prospective observational study over 24 months assessing anti-JCV AI and immunoglobulin levels in MS patients before and after initiation of ocrelizumab. RESULTS: No significant change in anti-JCV AI titers was observed 458 ± 300 days after initiation of ocrelizumab (n = 45, 0.7 ± 2.21 vs. 0.6 ± 2.06, p = 0.8). Seroconversion occurred in 1/20 initially anti-JCV seronegative patients. There was no correlation between changes in anti-JCV AI and immunoglobulins. CONCLUSION: Treatment with ocrelizumab is not associated with an increase in anti-JCV AI titers.
format Online
Article
Text
id pubmed-7522834
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-75228342020-10-06 Anti-JCV antibody index does not change during ocrelizumab-treatment Rempe, Torge Carlson, Aaron Miravalle, Augusto Gyang, Tirisham Victoria Mult Scler J Exp Transl Clin Short Report OBJECTIVE: To prospectively assess anti-JCV antibody index (AI) and its relationship to immunoglobulin levels in ocrelizumab-treated MS patients. METHODS: Monocentric prospective observational study over 24 months assessing anti-JCV AI and immunoglobulin levels in MS patients before and after initiation of ocrelizumab. RESULTS: No significant change in anti-JCV AI titers was observed 458 ± 300 days after initiation of ocrelizumab (n = 45, 0.7 ± 2.21 vs. 0.6 ± 2.06, p = 0.8). Seroconversion occurred in 1/20 initially anti-JCV seronegative patients. There was no correlation between changes in anti-JCV AI and immunoglobulins. CONCLUSION: Treatment with ocrelizumab is not associated with an increase in anti-JCV AI titers. SAGE Publications 2020-09-25 /pmc/articles/PMC7522834/ /pubmed/33029356 http://dx.doi.org/10.1177/2055217320960510 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Short Report
Rempe, Torge
Carlson, Aaron
Miravalle, Augusto
Gyang, Tirisham Victoria
Anti-JCV antibody index does not change during ocrelizumab-treatment
title Anti-JCV antibody index does not change during ocrelizumab-treatment
title_full Anti-JCV antibody index does not change during ocrelizumab-treatment
title_fullStr Anti-JCV antibody index does not change during ocrelizumab-treatment
title_full_unstemmed Anti-JCV antibody index does not change during ocrelizumab-treatment
title_short Anti-JCV antibody index does not change during ocrelizumab-treatment
title_sort anti-jcv antibody index does not change during ocrelizumab-treatment
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522834/
https://www.ncbi.nlm.nih.gov/pubmed/33029356
http://dx.doi.org/10.1177/2055217320960510
work_keys_str_mv AT rempetorge antijcvantibodyindexdoesnotchangeduringocrelizumabtreatment
AT carlsonaaron antijcvantibodyindexdoesnotchangeduringocrelizumabtreatment
AT miravalleaugusto antijcvantibodyindexdoesnotchangeduringocrelizumabtreatment
AT gyangtirishamvictoria antijcvantibodyindexdoesnotchangeduringocrelizumabtreatment

Ejemplares similares